Please sign in to follow a disease.
Ear-Zapping gadget could ease opioid withdrawal
NCT ID NCT07079826
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a wearable device called Sparrow Link that sends gentle electrical pulses to nerves in the ear to help reduce opioid withdrawal symptoms. About 50 hospitalized adults with opioid use disorder will receive either the active device or a sham version, along with standard care. Researchers will see if patients use the device consistently and if it lowers withdrawal severity, pain, and cravings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Sparrow Link device (transcutaneous auricular neurostimulation)
- What this could lead to
- If it works, this could offer a non-drug option to help manage opioid withdrawal symptoms in hospitals.
- What could go wrong
- This is a small, early feasibility study (50 people) testing whether patients will use the device at all. The sham control means any benefit may be placebo, and the device may cause discomfort or no improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Eligible participants must meet at least ONE of the following criteria: 1. Are continuing to experience opioid withdrawal symptoms: 1. Despite Maximal medical therapy with methadone, buprenorphine, full agonist opioids, or non-opioid medications, or 2. During tapering or detox from full agonist opioids. OR 2. Have chosen to decline methadone or buprenorphine but still require support for withdrawal symptoms and/or pain management. Additionally, participants must: * Be 18 years old or older. * Have active history of opioid use disorder. * Have a COWS score between 5-24 (Mild-moderate opioid withdrawal), indicating residual withdrawal symptoms. * Be able to provide informed consent. Exclusion Criteria: * History of or active seizure disorder. * Presence of a cardiac device (e.g., pacemaker, defibrillator). * Presence of a neurostimulator (e.g., deep brain stimulator, spinal cord stimulator). * Pregnant or lactating individuals. * COWS score ≥ 25 (Severe Withdrawal), requiring medical stabilization. * Abnormal ear Anatomy, ear Infections, or skin Conditions at Electrode Sites, including congenital malformations, post-surgical changes, significant scarring, open wounds, or hypersensitivity. * Active neurological disorders, such as traumatic brain injury, stroke, multiple sclerosis, or other conditions that may interfere with neurostimulation effects or autonomic regulation as assessed at the investigator's discretion. * Severe alcohol or benzodiazepine withdrawal that is not adequately controlled with medication, per investigator discretion. * Known or documented allergy to hydrocolloid adhesives, as evidenced in the medical record. * Evidence of active psychosis, as documented in the medical record or reported by clinical staff. * Non-English speakers, whose limited English proficiency precludes informed consent or meaningful participation in study assessments validated only in English.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Opioid use disorder (OUD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UPMC Presbyterian
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A bold community experiment takes on the opioid crisis
- Can daily text messages help curb opioid cravings and ease chronic pain?
- Ear-Zapping device may ease pain and opioid withdrawal
- New drug shows promise in calming opioid withdrawal
- Jail-Based PTSD therapy could curb overdose deaths after release
- Opioid tapering trial aims to help chronic pain patients cut back